Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma
- DOI
- 10.1016/j.seminoncol.2026.152570
- Published
- 2026-12
- Container
- Seminars in Oncology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.seminoncol.2026.152570,
title = {Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma},
author = {Vasiliki Bampiolaki-Genia and Konstantinos Grigoriou and Vasiliki Rammou and Dimitris Verveniotis and Michalis Liontos and Athanasios Kotsakis and Emmmanouil Saloustros},
year = {2026},
journal = {Seminars in Oncology},
doi = {10.1016/j.seminoncol.2026.152570},
url = {https://doi.org/10.1016/j.seminoncol.2026.152570}
}RIS
TY - JOUR TI - Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma AU - Vasiliki Bampiolaki-Genia AU - Konstantinos Grigoriou AU - Vasiliki Rammou AU - Dimitris Verveniotis AU - Michalis Liontos AU - Athanasios Kotsakis AU - Emmmanouil Saloustros PY - 2026 JO - Seminars in Oncology DO - 10.1016/j.seminoncol.2026.152570 UR - https://doi.org/10.1016/j.seminoncol.2026.152570 ER -
APA
Bampiolaki-Genia, V., Grigoriou, K., Rammou, V., Verveniotis, D., Liontos, M., Kotsakis, A., & Saloustros, E. (2026). Early pembrolizumab as salvage therapy in EMA-CO-refractory ultra-high-risk gestational choriocarcinoma. Seminars in Oncology. https://doi.org/10.1016/j.seminoncol.2026.152570
Source records
- crossref · retrieved 2026-11-10T10:24:17.647Z